TITLE

FIBRINOLYTIC THERAPY IN ACUTE DEEP THROMBOPHLEBITIS

AUTHOR(S)
Moser, Kenneth M.; Hajjar, George C.; Sulavik, Stephen B.
PUB. DATE
May 1961
SOURCE
Angiology;May1961, Vol. 12 Issue 5, p195
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Reports on the diagnosis of acute deep venous thrombosis by fibrinolytic therapy. Advantages of using the drug to grant rapid relief of acute signs and symptoms of the disease; Efficacy of fibrinolytic agents; Consideration of the relationship between the alterations in crating parameters of plasma fibrinolytic activity induced by a given dosage schedule of a given drug and the achievement of clot dissolution.
ACCESSION #
16430996

 

Related Articles

  • Piyavit from the Medicinal Leech Is a New Orally Active Anticoagulating and Antithrombotic Drug. Baskova, Isolda P.; Korostelev, Alexander N.; Chirkova, Lidiya D.; Zavalova, Ludmila L.; Basanova, Angelica V.; Doutremepuich, Christian // Clinical & Applied Thrombosis/Hemostasis;Jan1997, Vol. 3 Issue 1, p40 

    Piyavit, a novel pharmacological preparation allowed in Russia as an oral antithrombotic drug for clinical use. contains medicinal leech saliva as the main source of biologically active substances that inhibit platelet-vascular and plasmic hemostasis and provide thrombolysis. It is shown that...

  • Current Clinical Use of Reteplase for Thrombolysis: A Pharmacokinetic-Pharmacodynamic Perspective. Martin, U.; Kaufmann, B.; Neugebauer, G. // Clinical Pharmacokinetics;1999, Vol. 36 Issue 4, p265 

    Clinical evaluation of a new thrombolytic agent should start with a dose that provides adequate efficacy and has an acceptably low bleeding risk; this results in a narrow therapeutic window at the upper end of the dose-response curve. Angiographic patency of the infarct-related artery is still...

  • Are We Using Fibrinolytic Agents Often Enough? Marder, Victor J. // Annals of Internal Medicine;Jul80 Part 1, Vol. 93 Issue 1, p136 

    Editorial. Addresses the reluctance of physicians to use fibrinolytic therapy. Explanation for such attitude; Mechanism of action of fibrinolytic agents; Acceptance of heparin therapy.

  • Current Status of Pharmacological Thrombolytic Therapy and Mechanical Thrombectomy for the Treatment of Acute Deep Venous Thrombosis. Kiernan, Thomas J.; Cepeda, Beatriz; Kiernan, Gareth D.; Yan, Bryan P. // Cardiovascular & Hematological Agents in Medicinal Chemistry;2009, Vol. 7 Issue 1, p12 

    Deep venous thrombosis (DVT) is a highly prevalent clinical problem associated with significant mortality and morbidity. In the United States alone, it is estimated that DVT affects approximately 50 per 100,000 people per year. This results in >600,000 inpatient and outpatient treatments per...

  • Techniques and Results of Catheter-Directed Deep Venous Thrombolysis. Cragg, Andrew H. // Vascular Surgery;May/Jun1997, Vol. 31 Issue 3, p311 

    Discusses techniques and results of catheter-directed deep venous thrombolysis. Causes of venous stasis; Collection of data with regard to the efficacy of venous lysis; Information on systemic peripheral infusion of a lytic agent.

  • Alteplase improves stroke outcome up to 4.5 hours. Mayor, Susan // British Journal of Hospital Medicine (17508460);Nov2008, Vol. 69 Issue 11, p613 

    The article reports on the European Cooperative Acute Stroke Study (ECASS) on alteplase drug. It shows that thrombolysis with alteplase reduces the risk of patients with mild to moderate stroke when given within 4.5 hours of symptom onset. More specifically, patients treated with alteplase had a...

  • THE USE OF FIBRINOLYSIN IN NONHOSPITALIZED PATIENTS. Fillmore, A. James // Angiology;May1961, Vol. 12 Issue 5, p174 

    Presents several cases of fibrinolysin in nonhospitalized patients with disease in the digestive organ. Effectiveness of combined fibrinolytic-anticoagulant therapy for the diagnosis of an 80-year old widow suffering from acute insufficiency of the basilar artery system; Significance of...

  • Prethrombotic State Due to Hypercoagulability in Patients with Permanent Transvenous Pacemakers. Ito, Tatsuo; Tanouchi, Jun; Kato, Junji; Nishino, Masami; Iwai, Kunimitsu; Tanahashi, Hideo; Hori, Masatsugu; Yamada, Yoshio; Kamada, Takenobu // Angiology;Oct1997, Vol. 48 Issue 10, p901 

    Venous thrombosis is a relatively usual but serious complication of permanent transvenous pacing. However, the pathogenesis bas not been defined. To clarify underlying abnormalities in the coagulation-fibrinolysis system in patients with permanent transvenous pacemakers, we measured serum levels...

  • Edoxaban: A Review in Deep Vein Thrombosis and Pulmonary Embolism. Shirley, Matt; Dhillon, Sohita // Drugs;Nov2015, Vol. 75 Issue 17, p2025 

    Edoxaban (Lixiana, Savaysa) is an oral, direct factor Xa inhibitor which has recently been approved for use in the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) [collectively, venous thromboembolism (VTE)] and for the prevention of recurrent VTE. This article reviews the...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics